Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Background: The neutralizing ability of sotrovimab and casirivimab/imdevimab against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is attenuated in the subvariant BA.5. However, the efficacy of sotrovimab in the clinical setting remains to be investigated. Methods: Patients admitt...

Full description

Bibliographic Details
Main Authors: Kana Fujimoto, Satoru Mutsuo, Yuto Yasuda, Soichi Arasawa, Noriyuki Tashima, Daisuke Iwashima, Ken-ichi Takahashi
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Infectious Disease Reports
Subjects:
COVID-19
SARS-CoV-2
S antibody
sotrovimab
remdesivir
Online Access:https://www.mdpi.com/2036-7449/14/6/99

Internet

https://www.mdpi.com/2036-7449/14/6/99

Similar Items